KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,616,305 | -29.8% | 243,151 | -2.3% | 0.00% | 0.0% |
| Q4 2022 | $3,729,465 | +8.4% | 248,963 | -7.0% | 0.00% | 0.0% |
| Q3 2022 | $3,439,000 | +27.9% | 267,766 | -3.5% | 0.00% | 0.0% |
| Q2 2022 | $2,688,000 | -2.5% | 277,384 | 0.0% | 0.00% | – |
| Q1 2022 | $2,757,000 | -22.1% | 277,384 | -7.7% | 0.00% | -100.0% |
| Q4 2021 | $3,538,000 | -23.0% | 300,641 | -25.4% | 0.00% | 0.0% |
| Q3 2021 | $4,592,000 | -18.2% | 403,200 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $5,617,000 | +203.1% | 403,200 | +302.8% | 0.00% | – |
| Q1 2021 | $1,853,000 | +4.7% | 100,100 | 0.0% | 0.00% | – |
| Q4 2020 | $1,769,000 | +44.2% | 100,100 | +25.0% | 0.00% | – |
| Q3 2020 | $1,227,000 | +109.7% | 80,100 | +137.6% | 0.00% | – |
| Q2 2018 | $585,000 | – | 33,719 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |